Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Respiratorius

Respiratorius
1999 FOUNDED
PUBLIC STATUS
RESP STOCK SYMBOL
$0.13 SHARE PRICE (As of Friday Closing)
Description

Respiratorius AB develops pharmaceutical drugs to treat two of the most common diseases in the world: Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Stock Exchange
SAT
Primary Office
  • Magistratsvagen 10
  • 223 81 Lund
  • Sweden

+46 070-922 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Respiratorius’s full profile, request a free trial.

Respiratorius Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.12 - $0.26 $19.8M $0.13 188K 157M

Respiratorius Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 25,523 25,529 33,339 32,956
Revenue 0 0 0 0
EBITDA (348) (357) (312) (265)
Net Income (582) (594) (577) (567)
Total Assets 1,792 2,463 3,799 1,507
Total Debt 0 6 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Respiratorius Executive Team (1)

Name Title Board
Seat
Contact
Info
Johan Drott President & Chief Executive Officer